Bioline RX ISIN: US09071M2052

Kurs zur Bioline RX Aktie
1,27 USD
-1,93 %-0,03
21. May, 02:00:00 Uhr, Nasdaq
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Luecke
Luecke, 25. Mär 16:57
Gibts was neues ?
Summer.76
Summer.76, 16. Mär 13:12
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/biolinerx-reports-year-end-2021-financial-results-and-provides-corporate-update-301503962.html - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF versus plerixafor plus G-CSF - Cash and cash equivalents at December 31, 2021 of $57.1 million
Tobias1981
Tobias1981, 3. Mär 13:52
Jepp...sieht nach langer Zeit Mal wieder ganz gut aus
A
AceTrunk, 3. Mär 13:36
360 Mio. Umsatz bei einer Marktkapitalisierung von 70 mio. Dollar 🤔 der Kurs könnte heute noch explodieren 😎
A
AceTrunk, 3. Mär 13:35
Accordingly, we believe our product has the potential to become the new standard of care for all multiple myeloma patients undergoing autologous stem cell transplantation, and potentially for other indications as well, addressing a market with estimated potential revenues of more than $360 million in the US alone.
A
AceTrunk, 3. Mär 13:34
https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-additional-positive-results-pharmacoeconomic
J
Jaguar_power, 26.01.2022 18:02
@AceTrunk Bin nochmal auf deutsch... Sieht nach positiven Nachrichten aus und trotzdem schießt die Aktien nicht nach oben,, 🤔??
A
AceTrunk, 18.01.2022 14:50
TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding Motixafortide as a novel stem-cell mobilization agent for autologous bone marrow transplantation in multiple myeloma patients. The purpose of the meeting was to obtain agreement from the FDA on the content of the proposed NDA and, in particular, to confirm that the Company's single Phase 3 pivotal study, GENESIS, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA submission, which the Company continues to anticipate will occur in H1 2022. "We are highly encouraged by the collaborative pre-NDA meeting that we held with the FDA, and having confirmed alignment with the agency, our NDA submission remains on track for the first half of this year," stated Philip Serlin, Chief Executive Officer of BioLineRx. "This successful meeting continues the positive momentum generated from the compelling results of our GENESIS Phase 3 study, which demonstrate a highly significant improvement over the current standard of care, alongside the positive results of the pharmacoeconomic study that we reported more recently. As a result, Motixafortide, if approved, has the potential to become the standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation, especially in light of new and more intense induction treatment regimens given to these patients, which make stem-cell mobilization more difficult than ever before," concluded Mr. Serlin. In May 2021, BioLineRx announced positive top-line results from its GENESIS Phase 3 trial of Motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients. The study met all primary and secondary endpoints with a very high degree of statistical significance (p<0.0001). Importantly, ~90% of patients went directly to transplantation after mobilizing the optimal number of stem cells following only one administration of Motixafortide and in only one apheresis session.
A
AceTrunk, 18.01.2022 14:20
https://www.conferencecalltranscripts.com/summary/?id=10327054
Tobias1981
Tobias1981, 13.10.2021 21:59
Endlich geht es Mal wieder in die richtige Richtung. Habe trotz des Anstiegs nachgelegt.
Kommentare
1 Bioline RX Hauptdiskussion
Kursdetails
Geld (bid) 1,27 (700)
Brief (ask/offer) 1,30 (12.200)
Spread 2,31
Geh. Stück 118 Tsd.
Eröffnung 1,25
Vortag 1,30
Tageshoch 1,31
Tagestief 1,25
52W Hoch 3,62
52W Tief 1,01
Tagesvolumen
in EUR gehandelt 0 Stk
in USD gehandelt 118 Tsd. Stk
in GBP gehandelt 0 Stk
Gesamt 118 Tsd. Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 1,19 1,25 1653027010 20. May 1,19 EUR
Berlin 1,12 1,31 1653076356 20. May 1,22 EUR
Düsseldorf 1,15 1,27 1653067848 20. May 1,12 EUR
München 1,16 1,27 1653026491 20. May 1,20 EUR
Stuttgart 1,16 1,27 1653039821 20. May 1,18 EUR
Nasdaq 1,27 1,30 1653091200 02:00 118.304 Stk 1,27 USD
AMEX 1653076920 20. May 100 Stk 1,04 USD
Tradegate 1,15 1,28 1653078426 20. May 1,22 EUR
Lang & Schwarz 1,20 1,23 1653080282 20. May 1,22 EUR
London 1652105508 9. May 1,24 GBP
Gettex 1,16 1,28 1653075781 20. May 1,21 EUR
Baader Bank 1,16 1,28 1653072661 20. May 1,22 EUR
TTMzero RT 1653076801 20. May 1,22 EUR
ges. 118.404 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
82,0 Mio.
Anzahl der Aktien
47,7 Mio.
Grundlegende Daten zur Bioline RX Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.